Welcome to our dedicated page for Emergent BioSolutions SEC filings (Ticker: EBS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Emergent BioSolutions filings document an operating public-health company with NYSE-listed common stock under the symbol EBS. Its Form 8-K reports cover financial results, investor presentations, Regulation FD materials, debt prepayments, credit agreements, and other capital-structure events tied to its term loan and asset-based revolving facility.
Proxy and annual-meeting filings describe board elections, director appointments, committee service, auditor ratification, executive compensation, equity awards, and stockholder voting results. The filing record also captures governance disclosures for a company supplying NARCAN® Nasal Spray, ACAM2000®, and other medical countermeasure and bioservices products.
Emergent BioSolutions Inc. held its 2026 annual meeting of stockholders, where all management proposals, including director elections, auditor ratification, executive pay, and an equity plan amendment, were approved. A total of 40,346,672 shares were present or represented by proxy, representing 78.12% of the 51,644,495 shares outstanding and entitled to vote as of March 6, 2026.
Stockholders elected four Class II directors to terms expiring at the 2029 annual meeting, ratified Ernst & Young LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved the 2025 executive compensation on an advisory basis. They also approved an amendment to the Amended and Restated Stock Incentive Plan to increase the shares available for equity awards, with 16,972,952 votes for and 14,023,162 against, indicating relatively divided views on additional equity-based compensation.
Emergent BioSolutions Inc ownership disclosure: Vanguard Capital Management reports beneficial ownership of 2,605,090 shares of Common Stock, representing 5.04% of the class. The filing states Vanguard has sole voting power over 347,095 shares and sole dispositive power over 2,605,090 shares. The filing is signed by Ashley Grim, Head of Global Fund Administration, dated 04/29/2026.
Emergent BioSolutions refinanced its main credit facilities by entering a new Term Loan Agreement and amending its asset-based revolving credit facility. The new structure centers on a $150 million Initial Term Loan plus a $75 million delayed draw term loan arranged by OrbiMed and Jefferies Finance.
The Term Loan bears interest at Term SOFR, with a 3.00% floor, plus 6.25% per annum, and carries a 1.00% annual fee on undrawn delayed draw amounts. It matures as late as April 16, 2031, subject to a springing maturity tied to Emergent’s 3.875% Senior Unsecured Notes due 2028. Proceeds from the Initial Term Loan and cash on hand fully repaid and terminated the company’s prior term credit agreement.
Emergent also amended its ABL facility with Wells Fargo, reducing the revolving commitment from $100 million to $50 million while extending its latest maturity to April 16, 2031 and adjusting covenants. The Term Loan and ABL now sit in a revised collateral and covenant framework, including leverage tests and mandatory prepayments from certain debt incurrence, asset sales, casualty proceeds and excess cash flow.
Emergent BioSolutions Inc ownership disclosure: Dimensional Fund Advisors reports beneficial ownership of 2,757,158 shares of Common Stock, representing 5.3% of the class. The filing shows sole voting power for 2,704,803 shares. The shares are owned by funds managed by Dimensional, which disclaims beneficial ownership.
Emergent BioSolutions Inc. senior vice president of Products Business Paul Anthony Williams reported an open-market sale of Common Stock. On April 1, 2026, he sold 4,000 shares at a weighted average price of $8.44 per share. The trades occurred within a price range of $8.34 to $8.54 and were executed under a pre-arranged Rule 10b5-1(c) trading plan adopted on November 14, 2025. Following this sale, Williams directly holds 62,681 shares of Emergent BioSolutions common stock.
Emergent BioSolutions Schedule 13G/A shows The Vanguard Group reports 0 shares beneficially owned of Common Stock as of 03/13/2026, representing 0% of the class. The filing cites an internal realignment and reliance on SEC Release No. 34-39538 that led certain Vanguard subsidiaries to report holdings separately. The form is signed on 03/26/2026 by Ashley Grim, Head of Global Fund Administration.
Emergent BioSolutions summarizes progress on its multi-year turnaround, reporting operational and balance-sheet improvements in 2025. The company says it improved cash by $100M, reduced debt by $110M, secured multiple U.S. government biodefense contracts, and expanded its naloxone franchise including exclusive rights to KLOXXADO.
The company also reports distribution of over 100 million doses of NARCAN® since 2016, FDA approval for raxibacumab drug product manufacturing at Winnipeg, a divestiture of the Baltimore‑Bayview facility for $36, and an announced investment agreement with Swiss Rockets AG. The board and governance items, annual meeting details, and investor contacts are provided.
Emergent BioSolutions Inc. is asking stockholders to vote at its 2026 virtual annual meeting on director elections, auditor ratification, executive pay and an increase to the share reserve under its stock incentive plan.
Stockholders will elect four Class II directors to terms ending in 2029, vote on ratifying Ernst & Young LLP as independent auditor for 2026, cast an advisory say-on-pay vote on 2025 compensation for named executive officers, and decide on expanding the Amended and Restated Stock Incentive Plan. The company highlights a turnaround in 2025, with total revenue of $742.9 million versus $1,043.6 million in 2024, net income of $52.6 million after a prior-year loss, and adjusted EBITDA of $205.0 million.
The proxy describes a heavily independent, skills-diverse board, detailed committee structure, and pay-for-performance compensation design emphasizing variable and equity-based pay. It also discloses major institutional holders and shows that executives and directors collectively beneficially own 6.0% of outstanding common stock as of March 6, 2026.
Emergent BioSolutions Inc. executive vice president and chief financial officer Richard S. Lindahl reported the expiration of two employee stock option awards. Stock options for 20,321 shares and 19,963 shares expired unexercised pursuant to their terms, and the footnotes state that no value was received upon expiration.